Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigation
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has announced two regulatory milestones for the company's investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live attenuated): the U.S. Food and Drug Administration (FDA) has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) status.
Click on this link for more information.
